However, PPARγ antagonism has been reported to protect against the progression of nonalcoholic fatty liver disease (NAFLD) (69) and to reduce foam cell formation (70–72). This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.